Notice2024-22102
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production Activity; Merck, Sharp & Dohme LLC; (Pharmaceutical Products for Research and Development); Rahway, New Jersey
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 26, 2024
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 187 (Thursday, September 26, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 187 (Thursday, September 26, 2024)]
[Notices]
[Page 78845]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-22102]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-50-2024]
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production
Activity; Merck, Sharp & Dohme LLC; (Pharmaceutical Products for
Research and Development); Rahway, New Jersey
Merck, Sharp & Dohme LLC submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Rahway, New Jersey, within Subzone 49Y. The notification conforming to
the requirements of the Board's regulations (15 CFR 400.22) was
received on September 18, 2024.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product and material/component would be added to the production
authority that the Board previously approved for the operation, as
reflected on the Board's website.
The proposed finished product for research and development is MK-
6878 HIV drug product (duty-free).
The proposed foreign-status material/component is MK-6878 HIV
active pharmaceutical ingredient (duty rate, 6.5%). The request
indicates that this material/component is subject to duties under
section 301 of the Trade Act of 1974 (section 301), depending on the
country of origin. The applicable section 301 decisions require subject
merchandise to be admitted to FTZs in privileged foreign status (19 CFR
146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#92f4e6e8d2e6e0f3f6f7bcf5fde4"><span class="__cf_email__" data-cfemail="2a4c5e506a5e584b4e4f044d455c">[email protected]</span></a>. The closing period for their receipt is November 5,
2024.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#e1a588808f84cfa7888f978493a19593808584cf868e97"><span class="__cf_email__" data-cfemail="501439313e357e16393e2635221024223134357e373f26">[email protected]</span></a>.
Dated: September 23, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-22102 Filed 9-25-24; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 26, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.